{"id":1584,"date":"2026-07-29T01:55:26","date_gmt":"2026-07-29T01:55:26","guid":{"rendered":"https:\/\/valutednews.com\/?p=1584"},"modified":"2026-07-29T01:55:26","modified_gmt":"2026-07-29T01:55:26","slug":"gsk-lays-out-plans-to-cut-costs-pursue-more-late-stage-drug-trials","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=1584","title":{"rendered":"GSK lays out plans to cut costs, pursue more late-stage drug trials"},"content":{"rendered":"
\"GSK<\/div>

<\/p>\n

\n

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.<\/p>\n<\/div>\n

\n

LONDON \u2014 Half a year into taking over the job, GSK CEO Luke Miels on Tuesday laid out his plans to turn the U.K. pharma giant into a more agile company with years of growth ahead.\u00a0<\/p>\n

A key step, Miels said, will be a three-year campaign to generate 1.9 billion pounds (about $2.5 billion) in annual savings by 2029, much of which will be reinvested to advance the company\u2019s late-stage pipeline. The company also now plans to start at least 20 Phase 3 trials this year, up from the 10 that it had disclosed at the beginning of 2026.\u00a0<\/p>\n

\u201cWe are step-by-step building a set of potential best-in-class products across our core therapy areas,\u201d Miels said, a list that includes some newer target areas \u2014 like oncology and liver disease<\/a> \u2014 as well as longtime GSK focuses like vaccines and HIV. Miels would not say Tuesday how many jobs would be cut under the savings drive.\u00a0<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t